Scope
Reference
CM/PHG/24/5716
Description
NHS National Framework for Lenalidomide, Pomalidomide & Thalidomide.
Offer reference number: CM/PHG/24/5716
Period of framework agreement: Dates detailed below, with an option or options to extend (at the discretion of the Authority) for a period or periods up to a total of 48 months.
Periods of call-offs under the framework agreement:
CM/PHG/24/5716/01– NHS National Framework for Lenalidomide, Pomalidomide & Thalidomide.
CESW: (Midlands and Southwest): 1st June 2026 – 31st May 2028
NWLN: (Northwest and London North): 1st June 2026 – 31st May 2028
LSNE: (London South and Northeast): 1st June 2026 – 31st May 2028
Commercial tool
Establishes a framework
Total value (estimated)
- £33,981,928 excluding VAT
- £40,778,314 including VAT
Above the relevant threshold
Contract dates (estimated)
- 1 June 2026 to 31 May 2028
- Possible extension to 31 May 2030
- 4 years
Description of possible extension:
option or options to extend (at the discretion of the Authority) for a period or periods up to a total of 48 months.
Options
The right to additional purchases while the contract is valid.
option or options to extend (at the discretion of the Authority) for a period or periods up to a total of 48 months.
Main procurement category
Goods
CPV classifications
- 33600000 - Pharmaceutical products
Contract locations
- UKC - North East (England)
- UKD - North West (England)
- UKE - Yorkshire and the Humber
- UKF - East Midlands (England)
- UKG - West Midlands (England)
- UKH - East of England
- UKI - London
- UKJ - South East (England)
- UKK - South West (England)
Lot 1. Lenalidomide
Description
Lenalidomide
CESW: (Midlands and Southwest): 1st June 2026 – 31st May 2028
NWLN: (Northwest and London North): 1st June 2026 – 31st May 2028
LSNE: (London South and Northeast): 1st June 2026 – 31st May 2028
Lot value (estimated)
- £1 excluding VAT
- £1 including VAT
Framework lot values may be shared with other lots
Same for all lots
CPV classifications, contract locations, contract dates and options are shown in the Scope section, because they are the same for all lots.
Lot 2. Pomalidomide
Description
Pomalidomide
CESW: (Midlands and Southwest): 1st June 2026 – 31st May 2028
NWLN: (Northwest and London North): 1st June 2026 – 31st May 2028
LSNE: (London South and Northeast): 1st June 2026 – 31st May 2028
Lot value (estimated)
- £1 excluding VAT
- £1 including VAT
Framework lot values may be shared with other lots
Same for all lots
CPV classifications, contract locations, contract dates and options are shown in the Scope section, because they are the same for all lots.
Lot 3. Thalidomide
Description
Thalidomide
CESW: (Midlands and Southwest): 1st June 2026 – 31st May 2028
NWLN: (Northwest and London North): 1st June 2026 – 31st May 2028
LSNE: (London South and Northeast): 1st June 2026 – 31st May 2028
Lot value (estimated)
- £1 excluding VAT
- £1 including VAT
Framework lot values may be shared with other lots
Same for all lots
CPV classifications, contract locations, contract dates and options are shown in the Scope section, because they are the same for all lots.
Framework
Maximum number of suppliers
Unlimited
Maximum percentage fee charged to suppliers
0%
Framework operation description
Please refer to the ITO Documents for the Operation Description
Award method when using the framework
With competition
Contracting authorities that may use the framework
Please refer to Document No. 09 in the
ITO Documents for the list of
Purchasing Points.
Participation
Particular suitability
Lot 1. Lenalidomide
Lot 2. Pomalidomide
Lot 3. Thalidomide
Small and medium-sized enterprises (SME)
Submission
Enquiry deadline
2 March 2026, 5:00pm
Tender submission deadline
9 March 2026, 1:00pm
Submission address and any special instructions
The procurement documents are
available for unrestricted and full direct
access, free of charge at https://health-family.force.com/s/Welcome
Additional information may be obtained
from the abovementioned address.
Tenders must be submitted to the
above mentioned address.
Tenders may be submitted electronically
Yes
Languages that may be used for submission
English
Award decision date (estimated)
16 March 2026
Award criteria
Lot 1. Lenalidomide
| Name | Description | Type |
|---|---|---|
| Price | Price is not the only award criterion and all criteria are stated in the procurement documentation |
Price |
Weighting description
Price is not the only award criterion and all criteria are stated only in the procurement documents.
Lot 2. Pomalidomide
Lot 3. Thalidomide
| Name | Description | Type |
|---|---|---|
| Price | Price is not the only award criterion and all criteria are stated in the procurement documentation |
Price |
Weighting description
Price is not the only award criterion and all criteria are stated in the procurement documentation
Other information
Applicable trade agreements
- Government Procurement Agreement (GPA)
Conflicts assessment prepared/revised
Yes
Procedure
Procedure type
Open procedure
Contracting authority
NHS England
- Public Procurement Organisation Number: PDPT-3135-BWWY
Wellington House, 133-135 Waterloo Rd
London
SE1 8UG
United Kingdom
Email: david.ford1@nhs.net
Website: https://www.england.nhs.uk/
Region: UKI45 - Lambeth
Organisation type: Public authority - central government